Abstract
Background. This prospective study assessed combined modality therapy of patients with International Union Against Cancer classification T1‐4 NO MO anal cancer. Methods. Protocol therapy consisted of a dose of 4000 cGy to the pelvis, anus, and perineum, followed by a 1000‐1300 cGy boost. Infusions of 5‐fluorouracil and mitomycin‐C were administered when radiation therapy began. A second infusion of 5‐fluorouracil was administered 28 days later. Biopsy was performed 6‐8 weeks after completion of treatment. Positive biopsy findings resulted in abdominal‐perineal resection. Results. Survival at 7 years for 50 eligible patients was 58%. White patients and those with favorable performance status had significantly better survival. Of the 46 patients evaluable for response, 34 had a complete response, 11 had a partial response, and I had no response. Seven‐year survival for partial responders was 53%. Freedom from locoregional progression was 80% at 7 years. Conclusion. Treatment with a combination of chemotherapy and radiation therapy is effective for patients with anal cancer. The investigation of methods of improving therapy is warranted. Cancer 1995; 76:1731–6.
Original language | English (US) |
---|---|
Pages (from-to) | 1731-1736 |
Number of pages | 6 |
Journal | Cancer |
Volume | 76 |
Issue number | 10 |
DOIs | |
State | Published - Nov 15 1995 |
Keywords
- anus
- cancer
- chemotherapy
- combination therapy
- radiation therapy
- survival rate
ASJC Scopus subject areas
- Oncology
- Cancer Research